kashi-health-logo

Kashi Clinical Laboratories
10101 SW Barbur Blvd, Suite 200
Portland, OR 97219

1 877 879-1815
1000 characters left

Contact Information

Other Information

Practice Information

Thank you for your interest in Kashi Health's genetic testing services.

Our genetic tests require guidance from a licensed healthcare provider. You may find a qualified provider from our list of approved professionals in the link below, or you may email your provider directly requesting that they contact us to request a genetic test. We wish you the best in your pursuit of healthy living.

1-877-879-1815

Narcolepsy

Narcolepsy is a chronic, debilitating sleep disorder which is characterized by cataplexy (i.e. sudden transient muscular weakness), sleep paralysis, disturbed night sleep and excessive daytime sleepiness.

Narcolepsy is caused by deficiencies in the hypothalamic neurotransmitter, hypocretin (also known as orexin), most likely through autoimmune-mediated cell death of the neurons producing this neurotransmitter. Hypocretin is a neuropeptide hormone that is responsible for controlling appetite and sleep patterns.

Clinical Utility:

Patients are typically booked for a sleep study to establish breathing, heart rate, brain activity, and other bodily functions during the night to determine abnormal patterns of sleep. Laboratory tests to diagnose narcolepsy are dependent on analysis of orexin levels in the cerebrospinal fluid (CSF), which requires a highly invasive and painful lumbar puncture.

Genetics can play an important role in certain patients with narcolepsy. One important predisposing genetic factor is the HLA-DQB1*06:02 allele in the DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype. Between 85 to 95 percent of narcoleptics with the symptom of sudden muscle weakness have this combination of alleles. HLA-DQB1*06:02 genotyping, can be particularly useful in helping to diagnose patients with the symptom of sudden muscle weakness with narcolepsy.

Method:

Kashi Clinical Laboratories utilizes a combination of PCR-SSO (polymerase chain reaction sequence specific oligonucleotide typing) and SBT (sequence based typing) for testing.

Kashi's in-house laboratory and experienced health professionals ensure that customer service is personal, timely, and tailored to every patient's needs.

What is the Next Step? 

Make Kashi Health's Genetic Testing part of your patient's treatment plan today. 

Questions? Please contact our customer service team at 877-879-1815 or 503-206-4989 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it. . We are available Monday through Friday, from 8:00 AM - 5:00 PM, Pacific Time.

 References
  1. Hinze-Selch D et al. In vivo and in vitro immune variables in patients with narcolepsy and HLA-DR2 matched controls. Neurology. 1998; 50:1149.
  2. Hor H et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet. 2010; 42:786.
  3. Mignot E et al. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep. 1997; 20:1012.
  4. Mignot E et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet. 2001; 68:686.
  5. Miyagawa T et al. Identification of a telomeric boundary of the HLA region with potential for predisposition to human narcolepsy. Immunogenetics. 2000; 52:12.